Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
US Department of Justice
Medtronic
Covington
Colorcon
Cipla
Moodys
Fuji
Daiichi Sankyo

Generated: September 22, 2018

DrugPatentWatch Database Preview

Cyclobenzaprine hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for cyclobenzaprine hydrochloride and what is the scope of cyclobenzaprine hydrochloride patent protection?

Cyclobenzaprine hydrochloride is the generic ingredient in three branded drugs marketed by Teva Pharms Intl, Apotex Inc, Twi Pharms Inc, Actavis Labs Fl Inc, Aurobindo Pharma, Frontida Biopharm, Invagen Pharms, Jubilant Cadista, Kvk Tech, Mylan Pharms Inc, Orit Labs Llc, Oxford Pharms, Pliva, Prinston Inc, Rubicon Res Pvt Ltd, Sandoz, Sun Pharm Inds Ltd, Upsher-smith Labs, Watson Labs, and Janssen Res And Dev, and is included in twenty-one NDAs. There are eight patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are fifteen drug master file entries for cyclobenzaprine hydrochloride. Eighty-three suppliers are listed for this compound. There is one tentative approval for this compound.

Pharmacology for cyclobenzaprine hydrochloride
Synonyms for cyclobenzaprine hydrochloride
0VE05JYS2P
1-Propanamine, 3-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-, hydrochloride
1-Propanamine,d]cyclohepten-5-ylidene)-N,N-dimethyl-, hydrochloride
10,11.delta.-Amitriptyline hydrochloride
10,11delta-Amitriptyline hydrochloride
202C239
3-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)propyl(dimethyl)ammonium chloride
3-(5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine hydrochloride
3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine Hydrochloride
3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine hydrochloride
3-(dibenzo[2,1-b:1',2'-e][7]annulen-11-ylidene)-N,N-dimethylpropan-1-amine;hydrochloride
303-53-7 (Parent)
5-(3-Dimethylaminopropylidene)-5H-dibenzo-(a,d)cycloheptene hydrochloride
5-(3-Dimethylaminopropylidene)dibenzo[a,e]cycloheptatriene hydrochloride
5-[3-(Dimethylamino)propylidene]-5H-dibenzo-[a,d]cycloheptene hydrochloride
5H-Dibenzo(a,d)cycloheptene-delta(sup 5)-gamma-propylamine, N,N-dimethyl-, hydrochloride
5H-Dibenzo(a,d)cycloheptene-delta5,gamma-propylamine, N,N-dimethyl-, hydrochloride
5H-Dibenzo(a,d)cycloheptene-delta5,gamma-propylamine, N,N-dimethyl-, hydrochloride (8CI)
5H-Dibenzo[a, N,N-dimethyl-, hydrochloride
5H-Dibenzo[a,.gamma.-propylamine, N,N-dimethyl-, hydrochloride
6202-23-9
AC-1916
AC1L2KN5
ACT06294
AK115687
AKOS015906329
Amrix
AN-14454
AS-15745
BCP9000565
C 4542
C-19294
C20H21N.HCl
CAS-6202-23-9
CC-26027
CCG-39312
CHEBI:3997
CHEMBL1200636
Cloben
CS-2981
CTK8F8847
Cyben
Cyclobenzaprine (hydrochloride)
Cyclobenzaprine HCL
Cyclobenzaprine hydrochloride (USP)
Cyclobenzaprine hydrochloride [USAN:USP]
Cyclobenzaprine hydrochloride [USAN]
Cyclobenzaprine Hydrochloride 1.0 mg/ml in Methanol (as free base)
Cyclobenzaprine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Cyclobenzaprine very low dose
CYCLOBENZAPRINEHCL
Cycloflex
D00772
D0NN8N
DIMETHYL(3-{TRICYCLO[9.4.0.0(3),?]PENTADECA-1(15),3,5,7,9,11,13-HEPTAEN-2-YLIDENE}PROPYL)AMINE HYDROCHLORIDE
DR001318
DSSTox_CID_25105
DSSTox_GSID_45105
DSSTox_RID_80672
DTXSID2045105
EINECS 228-264-4
EU-0100303
EUR-1002
Flexeril
Flexeril (TN)
Flexiban
FT-0603166
HMS1569I12
HMS1922I11
HY-B0740
KB-76226
LP00303
LS-60768
M-1230
MFCD00079039
Miosan
MK 130 hydrochloride
MK-130
MK-130 [AS THE BASE]
MLS002153815
MolPort-003-666-812
Multi-Relax
N,d]cycloheptene-.delta.,5.gamma.-propylamine, hydrochloride
N,d]cycloheptene-.delta.(sup5,.gamma.)-propylamine hydrochloride
N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Delta(5,gamma)-propylamine hydrochloride
N,N-Dimethyl-5H-dibenzo(a,d)cycloheptene-delta(sup 5,gamma)-propylamine hydrochloride
NCGC00013841-01
NCGC00013841-09
NCGC00093752-01
NCGC00093752-02
NCGC00093752-03
NCGC00093752-04
NCGC00093752-05
NCGC00095017-01
NCGC00095017-02
NCGC00095017-03
NCGC00095017-04
NCGC00260988-01
Novo-Cycloprine
NSC 169900
NSC 173379
NSC 78206
NSC-169900
NSC-173379
NSC-758414
NSC-78206
NSC169900
NSC173379
NSC758414
NSC78206
Pharmakon1600-01503207
PL053563
Prestwick_790
Proheptatrien monohydrochloride
Proheptatriene hydrochloride
Proheptatriene monohydrochloride
PubChem15660
PubChem18912
Q517
s4283
SC-18388
SCHEMBL41376
SMR000326702
SPECTRUM1503207
SR-01000075761
SR-01000075761-1
ST24041508
ST51054170
Tabradol
Tensodox
TNX-102
TNX-102 SL
TNX-105
Tonmya
Tox21_110040
Tox21_110040_1
Tox21_500303
UNII-0VE05JYS2P
VXEAYBOGHINOKW-UHFFFAOYSA-N
W-105056
WLN: L C676 BHJ B3N1&1 &GH
Tentative approvals for CYCLOBENZAPRINE HYDROCHLORIDE
Applicant Application No. Strength Dosage Form
➤ Try a Free Trial➤ Try a Free Trial30MGCAPSULE, EXTENDED RELEASE; ORAL
➤ Try a Free Trial➤ Try a Free Trial15MGCAPSULE, EXTENDED RELEASE; ORAL

US Patents and Regulatory Information for cyclobenzaprine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds Ltd CYCLOBENZAPRINE HYDROCHLORIDE cyclobenzaprine hydrochloride TABLET;ORAL 078722-002 May 12, 2008 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Frontida Biopharm CYCLOBENZAPRINE HYDROCHLORIDE cyclobenzaprine hydrochloride TABLET;ORAL 073541-002 Apr 6, 2006 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-001 Feb 1, 2007 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for cyclobenzaprine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Res And Dev FLEXERIL cyclobenzaprine hydrochloride TABLET;ORAL 017821-001 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Janssen Res And Dev FLEXERIL cyclobenzaprine hydrochloride TABLET;ORAL 017821-002 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Janssen Res And Dev FLEXERIL cyclobenzaprine hydrochloride TABLET;ORAL 017821-002 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
US Department of Justice
Medtronic
Covington
Colorcon
Cipla
Moodys
Fuji
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.